Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 27,31 € (+66,73%). Mediana wynosi 29,99 € (+83,09%).
| Kupuj |
25 |
| Trzymaj |
11 |
| Sprzedaj |
1 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit
A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » Więcej na de.investing.com
Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference
At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » Więcej na de.investing.com
Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results
Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » Więcej na de.investing.com
FDA grants Acadia fast-track status for Alzheimer's drug remlifanserin
The FDA has granted fast-track status to Acadia’s compound remlifanserin for the treatment of hallucinations and delusions in Alzheimer’s psychosis. Acadia has completed patient recruitment for the Phase 2 portion of the RADIANT program and expects topline results in September–October 2026; Phase 3 screening and recruitment are already underway. Remlifanserin is an inverse agonist at the 5-HT2A receptor intended to avoid direct dopamine blockade and related safety issues. » Więcej na de.investing.com
Acadia Pharmaceuticals insider sells nearly half of direct holdings
James Kihara, Principal Accounting Officer at Acadia Pharmaceuticals, sold 11,421 shares in an open-market transaction on June 26, 2026—about 46.6% of his direct holdings—at a weighted average price of $26.08, leaving him with 13,088 shares. The sale, executed under a pre-established Rule 10b5-1 plan, was his largest single open-market disposition and coincided with a share rally after an EMA recommendation for Daybue. Company fundamentals remain strong, with Q1 2026 revenue of $268.1 million and ongoing late-stage pipeline programs. The filings show no derivative or indirect holdings were involved, and recent larger sales reflect reduced available capacity rather than disclosed discretionary changes in strategy. » Więcej na finance.yahoo.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 302,19 mln | 27,28% |
| Zysk brutto | 271,21 mln | 23,85% |
| Zysk netto | 47,25 mln | 22,74% |
| EBITDA | 71,02 mln | 75,28% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 2,94 mld € |
Liczba akcji | 172,83 mln |
Maksimum/minimum z 52 tygodni | 28,13 € - 14,41 € |
| Dywidendy | Nie |
Beta | 0,89 |
C/Z (PE Ratio) | 8,80 |
PEG (PEG Ratio) | 0,24 |
C/WK (PB Ratio) | 2,33 |
C/S (PS Ratio) | 2,70 |
Profil spółki
ACADIA Pharmaceuticals Inc., firma biofarmaceutyczna, koncentruje się na opracowywaniu i komercjalizacji leków low-molecular (małocząsteczkowych), które odpowiadają na niezaspokojone potrzeby medyczne w zaburzeniach ośrodkowego układu nerwowego. Firma oferuje NUPLAZID (pimawanseryna) do leczenia halucynacji i urojeń związanych z psychozą w chorobie Parkinsona. W jej portfelu rozwojowym znajdują się: pimawanseryna, będąca w fazie 3 badań nad leczeniem psychozy w chorobie Alzheimera oraz objawów negatywnych schizofrenii; trofinetyd, nowy syntetyczny analog, będący w fazie 3 badań nad leczeniem zespołu Retta; ACP-044, nowy, pierwszy w swojej klasie, doustny nieopioidowy lek przeciwbólowy, będący w fazie 2 badań nad leczeniem ostrego i przewlekłego bólu; oraz ACP-319, dodatni modulator allosteryczny receptora muskarynowego, będący w fazie 1 badań nad leczeniem schizofrenii i funkcji poznawczych w chorobie Alzheimera. ACADIA Pharmaceuticals Inc. została założona w 1993 roku i ma siedzibę w San Diego w Kalifornii.
| Nazwa | Acadia Pharmaceuticals |
| CEO | Catherine E. Owen Adams |
| Siedziba | San Diego,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 27.05.2004 |
| Pracownicy | 797 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | ACAD |
Frankfurt | DR6.F |
Düsseldorf | DR6.DU |
London | 0A4W.L |
SIX | DR6.SW |
München | DR6.MU |